Patients with BL tested positive for BRAF mutation showed a clear superiority of FOLFOXIRI plus bevacizumab over FOLFOXIRI plus cetuximab regarding PFS (10.4 months vs 5.7 months; HR 0.4; P = 0.009). This evidence concerns the gene BRAF and Burkitt lymphoma.